T Cell Modulator for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases (AIIDs) are inadequate in effectively preventing or managing these conditions, particularly in modulating T cell responses to reduce inflammation and immune system aberrations.
Innovation Solution
The use of T cell modulators, such as 6-(4-tert-butylphenoxy)pyridin-3-amine, which expands regulatory T cells and modulates immune responses to prevent or treat AIIDs by reducing inflammation and preventing Graft-versus-Host Disease (GvHD).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional T cell modulation approaches are used, then immune suppression is achieved, but the treatment effectiveness is insufficient and inflammation persists
Solution Approach 1:
The patent changes the parameter of T cell modulation by introducing a specific small molecule compound that selectively targets regulatory T cells, transforming the treatment approach from general immune suppression to precise Treg cell expansion, thereby improving treatment effectiveness while reducing harmful inflammation
Solution Approach 2:
The small molecule compound acts as an intermediary substance that mediates between the immune system and the disease state by selectively binding to and expanding regulatory T cells, which then serve as intermediaries to suppress pathological immune responses and reduce inflammation
2Duration of action of moving object
If immune suppressive drugs are used, then inflammation is reduced, but treatment options are limited and disease progression is not effectively delayed
Solution Approach 1:
The patent introduces a novel small molecule compound with a specific chemical structure that represents a new parameter in immune modulation therapy, expanding treatment options beyond existing immune suppressive drugs and achieving effective delay of disease progression through selective Treg cell expansion
Solution Approach 2:
The patent combines the small molecule compound with pharmaceutical acceptable carriers to create a composite pharmaceutical composition that integrates the active Treg-modulating agent with delivery systems, thereby expanding treatment versatility and improving duration of action
Data Source
AI summary
The present invention relates to methods for the prevention, delay of progression or treatment of an autoimmune and inflammatory disease (AIID) in a subject.